On Sept. 22, The Pink Sheet, a medical trade publication, reported the FDA had said that Pfizer received an "approvable letter" from the FDA. Such letters are not approvals but instead a kind of delay, saying that most of the data needed for approval are in but that additional steps need to be taken if the drug is to reach the market.